Risk of Depression after Venous Thromboembolism in Patients with Hematological Cancer: A Population-Based Cohort Study

Abstract

Background Venous thromboembolism (VTE) may complicate the clinical course of cancer patients and add to their psychological burden.

Objectives We aimed to investigate the association between VTE and risk of subsequent depression in patients with hematological cancer.

Patients and Methods We conducted a population-based cohort study using Danish national health registries. Between 1995 and 2020, we identified 1,190 patients with hematological cancer and incident VTE diagnosed within 6 months before to 1 year after cancer diagnosis. A comparison cohort of patients with hematological cancer without VTE (n = 5,325) was matched by sex, year of birth, cancer type, and year of cancer diagnosis. Patients were followed until diagnosis of depression, emigration, death, study end (2021), or for a maximum of 3 years. Depression was defined as hospital discharge diagnosis of depression or ≥1 prescription for antidepressants. Absolute risks of depression were computed with cumulative incidence functions, treating death as competing event. Hazard ratios (HRs) with 95% confidence intervals (CIs) were computed using Cox proportional hazards regression models, adjusting for comorbidities.

Results Depression was observed in 158 hematological cancer patients with and 585 without VTE. The 3-year absolute risks of depression were 13.3% (95% CI: 11.5–15.3%) in the VTE cancer cohort and 11.1% (95% CI: 10.3–12.0%) in the comparison cancer cohort, corresponding to a risk difference of 2.2% (95% CI: -1.8–6.5%). VTE was associated with an increased relative risk of depression (adjusted HR: 1.56, 95% CI: 1.28–1.90).

Conclusion VTE was associated with an elevated risk of subsequent depression in patients with hematological cancer.

Keywords

epidemiology - hematological cancer - neoplasms - disorders - venous thromboembolism

Note

The Department of Clinical Epidemiology receives funding for other studies from companies in the form of research grants to (and administered by) Aarhus University (none of these studies has any relation to the present study).

Data Availability Statement

Individual-level patient data from this study cannot be made available to other researchers due to Danish privacy law, but can be obtained from the Danish Health Data Agency.

Authors' Contribution

D.S., E.H.-P., H.J., C.A., and H.T.S. contributed to study concept and design. E.H.-P. performed the statistical analysis. All authors contributed to interpretation of the data. D.S. drafted the manuscript. All authors critically revised the manuscript and approved the final version before submission.

Publikationsverlauf

Eingereicht: 06. Oktober 2023

Angenommen: 08. Dezember 2023

Accepted Manuscript online:
11. Dezember 2023

Artikel online veröffentlicht:
18. Januar 2024

• References

• 1 Sung H, Ferlay J, Siegel RL. et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; 71 (03) 209-249
• 2 Pulte D, Jansen L, Brenner H. Changes in long term survival after diagnosis with common hematologic malignancies in the early 21st century. Blood Cancer J 2020; 10 (05) 56
• 3 Adelborg K, Corraini P, Darvalics B. et al. Risk of thromboembolic and bleeding outcomes following hematological cancers: a Danish population-based cohort study. J Thromb Haemost 2019; 17 (08) 1305-1318
• 4 Mitchell AJ, Chan M, Bhatti H. et al. Prevalence of depression, anxiety, and adjustment disorder in oncological, haematological, and palliative-care settings: a meta-analysis of 94 interview-based studies. Lancet Oncol 2011; 12 (02) 160-174
• 5 Boyes AW, Girgis A, D'Este C, Zucca AC. Flourishing or floundering? Prevalence and correlates of anxiety and depression among a population-based sample of adult cancer survivors 6months after diagnosis. J Affect Disord 2011; 135 (1–3): 184-192
• 6 Raskob GE, Angchaisuksiri P, Blanco AN. et al; ISTH Steering Committee for World Thrombosis Day. Thrombosis: a major contributor to global disease burden. Arterioscler Thromb Vasc Biol 2014; 34 (11) 2363-2371
• 7 Mulder FI, Horváth-Puhó E, van Es N. et al. Venous thromboembolism in cancer patients: a population-based cohort study. Blood 2021; 137 (14) 1959-1969
• 8 Ay C, Pabinger I, Cohen AT. Cancer-associated venous thromboembolism: Burden, mechanisms, and management. Thromb Haemost 2017; 117 (02) 219-230
• 9 Noble S, Prout H, Nelson A. Patients' Experiences of LIving with CANcer-associated thrombosis: the PELICAN study. Patient Prefer Adherence 2015; 9 (09) 337-345
• 10 Noble SI, Finlay IG. Is long-term low-molecular-weight heparin acceptable to palliative care patients in the treatment of cancer related venous thromboembolism? A qualitative study. Palliat Med 2005; 19 (03) 197-201
• 11 Mockler A, O'Brien B, Emed J, Ciccotosto G. The experience of patients with cancer who develop venous thromboembolism: an exploratory study. Oncol Nurs Forum 2012; 39 (03) E233-E240
• 12 Seaman S, Nelson A, Noble S. Cancer-associated thrombosis, low-molecular-weight heparin, and the patient experience: a qualitative study. Patient Prefer Adherence 2014; 8 (08) 453-461
• 13 Font C, Nelson A, Garcia-Fernandez T, Prout H, Gee P, Noble S. Patients' experience of living with cancer-associated thrombosis in Spain (PELICANOS). Support Care Cancer 2018; 26 (09) 3233-3239
• 14 Noble S, Nelson A, Scott J. et al. Patient Experience of Living With Cancer-Associated Thrombosis in Canada (PELICANADA). Res Pract Thromb Haemost 2019; 4 (01) 154-160
• 15 Benelhaj NB, Hutchinson A, Maraveyas AM, Seymour JD, Ilyas MW, Johnson MJ. Cancer patients' experiences of living with venous thromboembolism: a systematic review and qualitative thematic synthesis. Palliat Med 2018; 32 (05) 1010-1020
• 16 Jørgensen H, Horváth-Puhó E, Laugesen K, Brækkan S, Hansen J-B, Sørensen HT. Venous thromboembolism and risk of depression: a population-based cohort study. J Thromb Haemost 2023; 21 (04) 953-962
• 17 Tzeng N-S, Chung C-H, Chang S-Y. et al. Risk of psychiatric disorders in pulmonary embolism: a nationwide cohort study. J Investig Med 2019; 67 (06) 977-986
• 18 The Lancet Haematology. Thrombosis and mental health. Lancet Haematol 2022; 9 (08) e547
• 19 Schmidt M, Schmidt SAJ, Adelborg K. et al. The Danish health care system and epidemiological research: from health care contacts to database records. Clin Epidemiol 2019; 11 (11) 563-591
• 20 Schmidt M, Pedersen L, Sørensen HT. The Danish Civil Registration System as a tool in epidemiology. Eur J Epidemiol 2014; 29 (08) 541-549
• 21 Storm HH, Michelsen EV, Clemmensen IH, Pihl J. The Danish Cancer Registry–history, content, quality and use. Dan Med Bull 1997; 44 (05) 535-539
• 22 Gjerstorff ML. The Danish Cancer Registry. Scand J Public Health 2011; 39 (07) 42-45
• 23 Mors O, Perto GP, Mortensen PB. The Danish Psychiatric Central Research Register. Scand J Public Health 2011; 39 (07) 54-57
• 24 Schmidt M, Schmidt SA, Sandegaard JL, Ehrenstein V, Pedersen L, Sørensen HT. The Danish National Patient Registry: a review of content, data quality, and research potential. Clin Epidemiol 2015; 7: 449-490
• 25 Kildemoes HW, Sørensen HT, Hallas J. The Danish National Prescription Registry. Scand J Public Health 2011; 39 (07) 38-41
• 26 Sundbøll J, Adelborg K, Munch T. et al. Positive predictive value of cardiovascular diagnoses in the Danish National Patient Registry: a validation study. BMJ Open 2016; 6 (11) e012832
• 27 Galsklint J, Kold S, Kristensen SR, Severinsen MT, Gade IL. Validation of postsurgical venous thromboembolism diagnoses of patients undergoing lower limb orthopedic surgery in the Danish National Patient Registry. Clin Epidemiol 2022; 14: 191-199
• 28 Heide-Jørgensen U, Adelborg K, Kahlert J, Sørensen HT, Pedersen L. Sampling strategies for selecting general population comparison cohorts. Clin Epidemiol 2018; 10: 1325-1337
• 29 Bock C, Bukh JD, Vinberg M, Gether U, Kessing LV. Validity of the diagnosis of a single depressive episode in a case register. Clin Pract Epidemiol Ment Health 2009; 5 (01) 4
• 30 Lau B, Cole SR, Gange SJ. Competing risk regression models for epidemiologic data. Am J Epidemiol 2009; 170 (02) 244-256
• 31 von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 2007; 370 (9596) 1453-1457
• 32 Hou J-Z, Ye JC, Pu JJ. et al. Novel agents and regimens for hematological malignancies: recent updates from 2020 ASH annual meeting. J Hematol Oncol 2021; 14 (01) 66
• 33 Kekre N, Connors JM. Venous thromboembolism incidence in hematologic malignancies. Blood Rev 2019; 33: 24-32
• 34 Lund JL, Østgård LS, Prandoni P, Sørensen HT, de Nully Brown P. Incidence, determinants and the transient impact of cancer treatments on venous thromboembolism risk among lymphoma patients in Denmark. Thromb Res 2015; 136 (05) 917-923
• 35 McGee G, Haneuse S, Coull BA, Weisskopf MG, Rotem RS. On the nature of informative presence bias in analyses of electronic health records. Epidemiology 2022; 33 (01) 105-113